Guggenheim Maintains Buy on Coherus Oncology, Lowers Price Target to $10

Benzinga Newsdesk www.benzinga.com Negative 53.4%

Neg 53.4% Neu 0% Pos 0%

Guggenheim analyst Paul Jeng maintains Coherus Oncology (NASDAQ:CHRS) with a Buy and lowers the price target from $12 to $10.